| Chronic Obstructive Airway Disease
Bevespi Aerosphere vs Breo Ellipta
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Bevespi Aerosphere vs Breo Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBreo Ellipta has a higher rate of injection site reactions vs Bevespi Aerosphere based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Breo Ellipta but not Bevespi Aerosphere, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bevespi Aerosphere
Breo Ellipta
At A Glance
Oral inhalation
Twice daily
LAMA/LABA combination
Oral inhalation
Once daily
ICS/LABA combination
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
- Asthma
Dosing
Chronic Obstructive Airway Disease 2 inhalations (glycopyrrolate 18 mcg and formoterol fumarate 9.6 mcg) twice daily in the morning and evening by oral inhalation; do not exceed two inhalations twice daily.
Chronic Obstructive Airway Disease 1 actuation of BREO ELLIPTA 100/25 mcg once daily by oral inhalation; use a short-acting beta2-agonist for breakthrough symptoms between doses.
Asthma Adults >=18 years: 1 actuation of BREO ELLIPTA 100/25 mcg or 200/25 mcg once daily by oral inhalation; pediatric patients 12-17 years: 1 actuation of BREO ELLIPTA 100/25 mcg once daily; pediatric patients 5-11 years: 1 actuation of BREO ELLIPTA 50/25 mcg once daily; maximum dose is 1 inhalation of BREO ELLIPTA 200/25 mcg once daily.
Contraindications
- Use of a long-acting beta2-adrenergic agonist (LABA), including formoterol fumarate, without an inhaled corticosteroid in patients with asthma
- Hypersensitivity to glycopyrrolate, formoterol fumarate, or any component of the product
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any excipient
Adverse Reactions
Most common (>=2%) Cough, urinary tract infection
Serious Paradoxical bronchospasm, hypersensitivity reactions including anaphylaxis, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Hypersensitivity, urinary retention
Most common (>=3%) nasopharyngitis, upper respiratory tract infection, oropharyngeal candidiasis, headache, back pain, pneumonia, bronchitis, sinusitis, cough, arthralgia, influenza, pharyngitis, pyrexia
Serious serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia, immunosuppression, hypercorticism, adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, growth effects, glaucoma, cataracts
Postmarketing palpitations, tachycardia, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, nervousness, paradoxical bronchospasm
Pharmacology
BEVESPI AEROSPHERE combines glycopyrrolate, a long-acting anticholinergic (LAMA) that inhibits M3 muscarinic receptors in airway smooth muscle to produce bronchodilation, with formoterol fumarate, a long-acting selective beta2-adrenoceptor agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.
Breo Ellipta combines fluticasone furoate, a synthetic trifluorinated ICS that inhibits inflammation via glucocorticoid receptor activation, with vilanterol, a LABA that relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors and increasing intracellular cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bevespi Aerosphere
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (5/12) · Qty limit (9/12)
Breo Ellipta
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Bevespi Aerosphere
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Breo Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Bevespi Aerosphere
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Breo Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bevespi Aerosphere.
No savings programs available for Breo Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Bevespi AerosphereView full Bevespi Aerosphere profile
Breo ElliptaView full Breo Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.